Overview
MLYS market data
Price History
MLYS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.59 – $47.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.3B · P/B 4.44.
Company News
Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) EstimateBenzinga · Aug 11, 2026, 8:06 PM
Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO PosterBenzinga · Jun 8, 2026, 11:20 AM
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)Globenewswire Inc · Jun 8, 2026, 11:15 AM
8-K filing — Mineralys Therapeutics, Inc. (MLYS)SEC EDGAR · Jun 3, 2026, 8:07 PM
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent FinancingGlobenewswire Inc · Jun 3, 2026, 11:15 AM
Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026Benzinga · May 18, 2026, 8:15 PM
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology PortfoliosBenzinga · May 18, 2026, 5:05 PM